Welcome to GSK’s product website

Here you will find information about GSK’s medicines and vaccines

I’m a UK healthcare professional

Important notice: this site is intended for UK healthcare professionals. By entering this site, you are confirming that you are a UK healthcare professional. This site may contain promotional information.

I’m a member of the UK public

This site is intended for members of the UK public, patients and their carers.

M.C. Last updated: March 2018. UK/COM/0106/15(2)

M.C. Last updated: March 2018. UK/COM/0106/15(2)

trelegy_pack
trelegy_logo

The only COPD Triple Therapy delivered in a single daily inhalation1


Order a Sample

chevron
[1] Trelegy Ellipta SmPC
key_selling_messages
key_selling_messages

What is Trelegy Ellipta?


Indication

Trelegy Ellipta is indicated for maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β2-agonist1

Dosing

The recommended and maximum dose of Trelegy Ellipta (92/55/22 mcg) is one inhalation once a day. If a dose is missed the next dose should be taken at the usual time the next day. No dose adjustments are required for special populations.1

trelegy_components
[1] Trelegy Ellipta SmPC

Meet Alexander*

  • AGE: 63
  • CAT SCORE: 15
  • FEV1: 50% predicted
  • EXACERBATIONS: One moderate exacerbation in the past year
  • SYMPTOMS: Breathlessness
  • CURRENT TREATMENT: ICS/LABA
* Fictional Patient

What would be your treatment goals for Alexander?

Increase Lung Function

lungs_icon

In the IMPACT trial, Trelegy Ellipta demonstrated superior improvement in lung function vs. Relvar Ellipta (fluticasone furoate/vilanterol) 92/22mcg at 52 weeks1

impact_lung_function_graph
1. Lipson DA et al. N Engl J Med. 2018; doi: 10.1056/NEJMoa1713901
Relvar Ellipta Prescribing Information

In the FULFIL study, Trelegy Ellipta demonstrated superior improvement in lung function vs. Symbicort Turbohaler (budesonide/formoterol) 320/9mcg at 24 weeks1

fulfil_lung_function_graph
1. Lipson DA et al. Am J Respir Crit Care Med. 2017; 196(4): 438-446.
plus_icon

Reduce Exacerbations

exacerbation_icon

In the IMPACT trial, Trelegy Ellipta demonstrated superior reduction in the rate of exacerbations vs. Relvar Ellipta (fluticasone furoate/vilanterol) 92/22mcg over 52 weeks (Primary Endpoint)1

impact_exacerbations_graph
Trelegy▼ Ellipta (fluticasone furoate/umeclidinium/vilanterol 92/55/22 mcg) is indicated as maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of a ICS and a LABA2
Relvar Ellipta (fluticasone furoate/vilanterol 92/22 mcg) is indicated for the symptomatic treatment of adults with COPD with a FEV1 <70% predicted normal (post-bronchodilator) with an exacerbation history despite regular bronchodilator therapy3
1. Lipson DA et al. N Engl J Med. 2018; doi: 10.1056/NEJMoa1713901. 2. Trelegy Ellipta SmPC 3. Relvar Ellipta SmPC
Relvar Ellipta Prescribing Information

In the FULFIL study, Trelegy Ellipta demonstrated significant reduction in the annual rate of exacerbations vs. Symbicort Turbohaler (budesonide/formoterol) 320/9mcg over 24 weeks1

fulfil_exacerbations_graph
1. Lipson DA et al. Am J Respir Crit Care Med. 2017; 196(4): 438-446.
plus_icon

Improve Quality of Life

qol_icon

In the IMPACT trial, Trelegy Ellipta significantly improved health-related QoL (SGRQ)* vs. Relvar Ellipta (fluticasone furoate/vilanterol) 92/22mcg at 52 weeks1

impact_lung_function_graph
*The SGRQ is a validated disease-specific health status assessment for use in asthma and COPD and a difference of 4 units or more is considered clinically meaningful.2
1. Lipson DA et al. N Engl J Med. 2018; doi: 10.1056/NEJMoa1713901.
2. Jones PW. COPD 2005
Relvar Ellipta Prescribing Information

In the FULFIL study, Trelegy Ellipta significantly improved health-related QoL (SGRQ)* vs. Symbicort Turbohaler (budesonide/formoterol) 320/9mcg at 24 weeks1

fulfil_qol_graph.png
*The SGRQ is a validated disease-specific health status assessment for use in asthma and COPD and a difference of 4 units or more is considered clinically meaningful.2
1. Lipson DA et al. Am J Respir Crit Care Med. 2017; 196(4): 438-446.
2. Jones PW. COPD 2005
plus_icon

Safety Profile

The safety profile of Trelegy Ellipta was consistent with the known profile of its components and no new safety signals were identified. In common with other corticosteroid-containing medicines, there is an increased risk of pneumonia in patients with COPD treated with Trelegy Ellipta.

Trelegy comes in the easy to use Ellipta inhaler1-3

With Ellipta, significantly fewer patients with COPD made critical errors* compared to other commonly used inhalers after reading the patient information leaflet (p<0.001 for all comparisons)1-3


Compare Ellipta: click on an icon


critical_errors_trelegy_vs_MDI_graph_beige
4.8x

fewer patients made a critical error* with Ellipta vs MDI (Ellipta 13%; MDI 60%, p<0.001)


  • Single-visit, placebo inhaler, crossover comparison in patients naive to Ellipta and the comparator inhaler (p<0.001)3
  • Adapted from van der Palen et al. 20163
  • *Defined as errors that are likely to result in no, or minimal,medication being delivered to the lung3
  1. Riley J et al. Int J Chron Obstruct Pulmon Dis 2016; 11:1873-1880.
  2. Svedsater H et al. BMC pulm Med 2013; 13:72-86.
  3. van der Palen J et al. NPJ Prim Care Respir Med 2016; 26:16079.
critical_errors_trelegy_vs_accuhaler_graph_beige
8.3x

fewer patients made a critical error* with Ellipta vs Accuhaler (Ellipta 5%; Accuhaler 44%, p<0.001)


  • Single-visit, placebo inhaler, crossover comparison in patients naive to Ellipta and the comparator inhaler (p<0.001)3
  • Adapted from van der Palen et al. 20163
  • *Defined as errors that are likely to result in no, or minimal,medication being delivered to the lung3
  1. Riley J et al. Int J Chron Obstruct Pulmon Dis 2016; 11:1873-1880.
  2. Svedsater H et al. BMC pulm Med 2013; 13:72-86.
  3. van der Palen J et al. NPJ Prim Care Respir Med 2016; 26:16079.
critical_errors_trelegy_vs_turbohaler_graph_beige
5.5x

fewer patients made a critical error* with Ellipta vs Turbohaler (Ellipta 8%; Turbohaler 44%, p<0.001)


  • Single-visit, placebo inhaler, crossover comparison in patients naive to Ellipta and the comparator inhaler (p<0.001)3
  • Adapted from van der Palen et al. 20163
  • *Defined as errors that are likely to result in no, or minimal,medication being delivered to the lung3
  1. Riley J et al. Int J Chron Obstruct Pulmon Dis 2016; 11:1873-1880.
  2. Svedsater H et al. BMC pulm Med 2013; 13:72-86.
  3. van der Palen J et al. NPJ Prim Care Respir Med 2016; 26:16079.
critical_errors_trelegy_vs_handihaler_graph_beige
3.4x

fewer patients made a critical error* with Ellipta vs Handihaler (Ellipta 14%; Handihaler 48%, p<0.001)


  • Single-visit, placebo inhaler, crossover comparison in patients naive to Ellipta and the comparator inhaler (p<0.001)3
  • Adapted from van der Palen et al. 20163
  • *Defined as errors that are likely to result in no, or minimal,medication being delivered to the lung3
  1. Riley J et al. Int J Chron Obstruct Pulmon Dis 2016; 11:1873-1880.
  2. Svedsater H et al. BMC pulm Med 2013; 13:72-86.
  3. van der Palen J et al. NPJ Prim Care Respir Med 2016; 26:16079.
critical_errors_trelegy_vs_breezhaler_graph_beige
3.5x

fewer patients made a critical error* with Ellipta vs Breezhaler (Ellipta 13%; Breezhaler 46%, p<0.001)


  • Single-visit, placebo inhaler, crossover comparison in patients naive to Ellipta and the comparator inhaler (p<0.001)3
  • Adapted from van der Palen et al. 20163
  • *Defined as errors that are likely to result in no, or minimal,medication being delivered to the lung3
  1. Riley J et al. Int J Chron Obstruct Pulmon Dis 2016; 11:1873-1880.
  2. Svedsater H et al. BMC pulm Med 2013; 13:72-86.
  3. van der Palen J et al. NPJ Prim Care Respir Med 2016; 26:16079.
critcal_errors_vs_alternatives critcal_errors_vs_alternatives

Fewer patients made a critical error* with Ellipta vs comparator inhalers

  • Single-visit, placebo inhaler, crossover comparison in patients naive to Ellipta and the comparator inhaler (p<0.001)3
  • Adapted from van der Palen et al. 20163
  • *Defined as errors that are likely to result in no, or minimal,medication being delivered to the lung3
  1. Riley J et al. Int J Chron Obstruct Pulmon Dis 2016; 11:1873-1880.
  2. Svedsater H et al. BMC pulm Med 2013; 13:72-86.
  3. van der Palen J et al. NPJ Prim Care Respir Med 2016; 26:16079.
cost

Cost

A lower cost (at £44.50) than commonly prescribed multiple inhaler Triple Therapy


See Price List
formulary

Formulary

Information to support commissioners and healthcare professionals when making a Trelegy formulary application


View Evidence

Get started with Trelegy Ellipta

Order a Sample
innoviva_logo

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.

Trelegy and Ellipta are registered trademarks of the GlaxoSmithKline group of companies

S.H. Last updated: August 2018. UK/TLY/0081/18